REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 209 filers reported holding REATA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $26,039,259 | +12.3% | 255,387 | +0.1% | 1.41% | +3.1% |
| Q1 2023 | $23,186,237 | +15.9% | 255,018 | -51.6% | 1.37% | +10.6% |
| Q4 2022 | $19,999,646 | +80.6% | 526,445 | +19.5% | 1.24% | +77.0% |
| Q3 2022 | $11,075,000 | +45.0% | 440,718 | +75.4% | 0.70% | +58.4% |
| Q2 2022 | $7,636,000 | +6.9% | 251,268 | +15.3% | 0.44% | +39.9% |
| Q1 2022 | $7,142,000 | +55.4% | 218,006 | +25.1% | 0.32% | +95.1% |
| Q4 2021 | $4,597,000 | -83.7% | 174,316 | -37.9% | 0.16% | -83.4% |
| Q3 2021 | $28,253,000 | -20.9% | 280,816 | +11.2% | 0.98% | -16.4% |
| Q2 2021 | $35,733,000 | +42.5% | 252,476 | +0.4% | 1.17% | +40.6% |
| Q1 2021 | $25,074,000 | +178.8% | 251,497 | +336.4% | 0.83% | +96.2% |
| Q2 2020 | $8,992,000 | -37.3% | 57,635 | -42.0% | 0.42% | -52.8% |
| Q1 2020 | $14,344,000 | -28.3% | 99,374 | +1.6% | 0.90% | +10.0% |
| Q4 2019 | $19,994,000 | -6.8% | 97,804 | -63.4% | 0.82% | -14.0% |
| Q3 2019 | $21,463,000 | -36.8% | 267,321 | -25.7% | 0.95% | -29.6% |
| Q2 2019 | $33,963,000 | +10.4% | 359,970 | 0.0% | 1.35% | +9.4% |
| Q1 2019 | $30,767,000 | +12.8% | 359,970 | -26.0% | 1.23% | -3.3% |
| Q4 2018 | $27,276,000 | -24.9% | 486,210 | +9.4% | 1.28% | +3.9% |
| Q3 2018 | $36,342,000 | +113.5% | 444,492 | -8.7% | 1.23% | +98.9% |
| Q2 2018 | $17,021,000 | +76.1% | 486,741 | +3.3% | 0.62% | +62.8% |
| Q1 2018 | $9,663,000 | -25.7% | 471,114 | +2.6% | 0.38% | -26.7% |
| Q4 2017 | $13,004,000 | -11.6% | 459,184 | -2.9% | 0.52% | -15.7% |
| Q3 2017 | $14,712,000 | +58.2% | 473,051 | +60.9% | 0.61% | +51.4% |
| Q2 2017 | $9,300,000 | +49.5% | 293,927 | +7.0% | 0.40% | +42.1% |
| Q1 2017 | $6,222,000 | +24.2% | 274,692 | +19.7% | 0.28% | +19.2% |
| Q4 2016 | $5,011,000 | -17.1% | 229,559 | +0.1% | 0.24% | -22.4% |
| Q3 2016 | $6,048,000 | +67.9% | 229,440 | +25.8% | 0.31% | +52.5% |
| Q2 2016 | $3,602,000 | – | 182,390 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |